2020
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts).
Stein S, Snider J, McCusker M, Miksad R, Alexander B, Castellanos E, Backenroth D, Schrock A, Madison R, Carson K, Ali S. Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts). Journal Of Clinical Oncology 2020, 38: 310-310. DOI: 10.1200/jco.2020.38.4_suppl.310.Peer-Reviewed Original ResearchComprehensive genomic profilingAdjusted hazard ratioGE cancersOverall survivalERBB2 copy numberERBB2 amplificationClinical outcomesUnadjusted Kaplan-Meier analysisCox proportional hazards modelMedian overall survivalKaplan-Meier analysisEsophageal cancer patientsProportional hazards modelLonger OSHazard ratioMedian ageCancer patientsHER2 expressionHER2 statusTherapy benefitHazards modelHER2Median TTDClinical databaseDiscordant tests
2019
KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US.
Uhlig J, Stein S, Lacy J, Kim H. KRAS mutation and microsatellite instability in colorectal cancer: Screening pattern and mutational landscape across the US. Journal Of Clinical Oncology 2019, 37: e15138-e15138. DOI: 10.1200/jco.2019.37.15_suppl.e15138.Peer-Reviewed Original ResearchOverall survivalColorectal cancerKRAS mutationsMicrosatellite instabilityNon-metastatic colorectal cancerPropensity scoreCox proportional hazards modelMetastatic colorectal cancerNational Cancer DatabasePatients' overall survivalProportional hazards modelMutational screeningDistinct mutational patternsPatient ageYounger patientsMutational prevalenceCancer DatabaseCancer factorsCRC siteFemale African AmericansHazards modelAcademic centersEast South CentralPatientsFemale Caucasians